This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Third-line enfortumab vedotin improved outcomes in metastatic urothelial carcinoma, per real-world data from the EV-301 trial ...

The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...

Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...

We expect investors to focus on the sales performance of Immunocore Holdings plc’s IMCR sole marketed drug, Kimmtrak ...

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its new drug application for zongertinib (BI 1810631) for the treatment of adult ...

Your doctor normally gives you targeted cancer drugs and immunotherapy to treat advanced melanoma. This is also called metastatic or stage 4 melanoma. The treatment for unresectable stage 3 melanoma ...

The US Food and Drug Administration (FDA) has granted priority review to Boehringer Ingelheim’s new drug application (NDA) ...

The Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application for zongertinib for the treatment of adult patients with ...